<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">avk</journal-id><journal-title-group><journal-title xml:lang="ru">Архивъ внутренней медицины</journal-title><trans-title-group xml:lang="en"><trans-title>The Russian Archives of Internal Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-6704</issn><issn pub-type="epub">2411-6564</issn><publisher><publisher-name>“SINAPS” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20514/2226-6704-2025-15-3-216-225</article-id><article-id custom-type="edn" pub-id-type="custom">QKHGQS</article-id><article-id custom-type="elpub" pub-id-type="custom">avk-2007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>Неинвазивные предикторы выраженной гистологической активности при хронических заболеваниях печени: роль матриксных металлопротеиназ</article-title><trans-title-group xml:lang="en"><trans-title>A Noninvasive Predictors of Significant Histological Activity in Chronic Liver Diseases: The Role of Matrix Metalloproteinases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5727-1640</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ягода</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yagoda</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ягода Александр Валентинович — д.м.н., профессор, заслуженный деятель науки РФ, заведующий кафедрой госпитальной терапии</p><p>Ставрополь </p></bio><bio xml:lang="en"><p>Alexander V. Yagoda — Doctor of Medical Sciences, Professor, Head of the Department of Hospital Therapy</p><p>Stavropol </p></bio><email xlink:type="simple">alexander.yagoda@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6392-8461</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корой</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Koroy</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Корой Павел Владимирович — д.м.н., профессор, профессор кафедры госпитальной терапии</p><p>Ставрополь </p></bio><bio xml:lang="en"><p>Pavel V. Koroy — MD, PhD, Professor, Professor of Department of Hospital Therapy</p><p>Stavropol </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-7244-3507</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дудов</surname><given-names>Т. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Dudov</surname><given-names>T. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дудов Темирлан Русланович — ассистент кафедры госпитальной терапии</p><p>Ставрополь </p></bio><bio xml:lang="en"><p>Temirlan R. Dudov — Assistant of Department of Hospital Therapy </p><p>Stavropol </p></bio><email xlink:type="simple">timur222123@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Ставропольский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Stavropol State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>05</month><year>2025</year></pub-date><volume>15</volume><issue>3</issue><fpage>216</fpage><lpage>225</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ягода А.В., Корой П.В., Дудов Т.Р., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Ягода А.В., Корой П.В., Дудов Т.Р.</copyright-holder><copyright-holder xml:lang="en">Yagoda A.V., Koroy P.V., Dudov T.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medarhive.ru/jour/article/view/2007">https://www.medarhive.ru/jour/article/view/2007</self-uri><abstract><p>Цель исследования: изучение прогностической значимости клинико-лабораторных маркеров печеночной патологии, в том числе компонентов системы матриксных металлопротеиназ (ММП), для выявления умеренной/выраженной активности при хронических заболеваниях печени (ХЗП). Материалы и методы. Обследовано 76 пациентов ХЗП вирусной или алкогольной этиологии в возрасте от 18 до 64 лет. Минимальная (индекс гистологической активности — ИГА 1-3 балла), слабовыраженная (ИГА 4-8 баллов), умеренная (ИГА 9-12 баллов) и выраженная морфологическая активность (ИГА более 12 баллов) выявлялись в 19 (25,0 %), 34 (44,7 %), 14 (18,4 %) и 9 (11,9 %) случаев соответственно. Методом иммуноферментного анализа определяли содержание в крови ММП-1, ММП-9, тканевого ингибитора матриксных металлопротеиназ-1 (ТИМП-1), рассчитывали соотношение ТИМП-1/ММП-1, ТИМП-1/ММП-9. Результаты. По данным многофакторной логистической регрессии, умеренная/выраженная гистологическая активность ХЗП была ассоциирована с показателями γ-глютамилтранспептидазы (ГГТ) (отношение шансов (ОШ) 1,016; 95 % доверительный интервал (ДИ) (1,006-1,024), р=0,001), международного нормализованного отношения (МНО) (ОШ 1,079; 95 % ДИ (1,028-1,132), р=0,002), соотношения ТИМП-1/ММП-9 (ОШ 0,554; 95 % ДИ (0,380-0,809), р=0,002). Комбинация этих параметров имела чувствительность 82,6 %, специфичность 92,5 % и точность 89,5 % в выявлении ИГА 9 и более баллов. Заключение. Увеличенные значения ГГТ и МНО, а также сниженное соотношение ТИМП-1/ММП-9 являются независимыми факторами риска умеренной/выраженной гистологической активности при ХЗП, что обусловлено их участием в процессах печеночного воспаления.</p></abstract><trans-abstract xml:lang="en"><p>Aim of investigation. To study the prognostic significance of clinical and laboratory markers of liver pathology, including components of the matrix metalloproteinase (MMP) system, to identify moderate/significant activity in chronic liver diseases (CLD). Materials and methods. 76 patients with CLD of viral or alcoholic etiology aged from 18 to 64 years were examined. Minimal (histological activity index — HAI 1-3 points), minor (HAI 4-8 points), moderate (HAI 9-12 points) and significant morphological activity (HAI more than 12 points) were detected in 19 (25.0 %), 34 (44.7 %), 14 (18.4 %) and 9 (11.9 %) of cases, respectively. Enzyme immunoassay was used to determine the blood levels of MMP-1, MMP-9, tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), and the of TIMP-1/MMP-1, TIMP-1/MMP-9 was calculated. Results. According to multivariate logistic regression data, moderate/significant histological activity of CLD was associated with γ-glutamyltranspeptidase (GGT) (odds ratio (OR) 1.016; 95 % confidence interval (CI) (1.006-1.024), p=0.001), international normalized ratio (INR) (OR 1.079; 95 % CI (1.028-1.132), p=0.002), and TIMP-1/MMP- 9 ratio (OR 0.554; 95 % CI (0.380-0.809), p=0.002). The combination of these parameters had sensitivity of 82.6 %, specificity of 92.5 % and accuracy of 89.5 % in detecting HAI of 9 or more points. Conclusion. The increased values of GGT and INR, as well as a reduced ratio of TIMP-1/MMP-9, are independent risk factors for moderate/significant histological activity in CLD, due to their participation in the processes of hepatic inflammation.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронические заболевания печени</kwd><kwd>гистологическая активность</kwd><kwd>матриксная металлопротеиназа-9</kwd><kwd>тканевой ингибитор матриксных металлопротеиназ-1</kwd><kwd>γ-глютамилтранспептидаза</kwd><kwd>международное нормализованное отношение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic liver diseases</kwd><kwd>histological activity</kwd><kwd>matrix metalloproteinase-9</kwd><kwd>tissue inhibitor of matrix metalloproteinases-1</kwd><kwd>γ-glutamyl transpep tidase</kwd><kwd>international normalized ratio</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Moon A.M., Singal A.G., Tapper E.B. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin. Gastroenterol. Hepatol. 2020; 18: 2650-2666. doi: 10.1016/j.cgh.2019.07.060</mixed-citation><mixed-citation xml:lang="en">Moon A.M., Singal A.G., Tapper E.B. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin. Gastroenterol. Hepatol. 2020; 18: 2650-2666. doi: 10.1016/j.cgh.2019.07.060</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Devarbhavi H., Asrani S.K., Arab J.P. et al. Global burden of liver disease: 2023 update. J. Hepatol. 2023; 79 (2): 516-537. doi: 10.1016/j.jhep.2023.03.017</mixed-citation><mixed-citation xml:lang="en">Devarbhavi H., Asrani S.K., Arab J.P. et al. Global burden of liver disease: 2023 update. J. Hepatol. 2023; 79 (2): 516-537. doi: 10.1016/j.jhep.2023.03.017</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jeng W., Papatheodoridis G., Lok A.S. F. Hepatitis B. Lancet. 2023; 401 (10381): 1039-1052. doi: 10.1016/s0140-6736(22)01468-4</mixed-citation><mixed-citation xml:lang="en">Jeng W., Papatheodoridis G., Lok A.S. F. Hepatitis B. Lancet. 2023; 401 (10381): 1039-1052. doi: 10.1016/s0140-6736(22)01468-4</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Stockdale A.J., Kreuels B., Henrion M.Y. R. et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J. Hepatol. 2020; 73: 523-532. doi: 10.1016/j.jhep.2020.04.008</mixed-citation><mixed-citation xml:lang="en">Stockdale A.J., Kreuels B., Henrion M.Y. R. et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J. Hepatol. 2020; 73: 523-532. doi: 10.1016/j.jhep.2020.04.008</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Petagine L., Zariwala M.G., Patel V.B. Alcoholic liver disease: current insights into cellular mechanisms. World J. Biol. Chem. 2021; 12 (5): 87-103. doi: 10.4331/wjbc.v12.i5.87.</mixed-citation><mixed-citation xml:lang="en">Petagine L., Zariwala M.G., Patel V.B. Alcoholic liver disease: current insights into cellular mechanisms. World J. Biol. Chem. 2021; 12 (5): 87-103. doi: 10.4331/wjbc.v12.i5.87.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update. J. Hepatol. 2021; 75 (3): 659-689. doi: 10.1016/j.jhep.2021.05.025</mixed-citation><mixed-citation xml:lang="en">EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update. J. Hepatol. 2021; 75 (3): 659-689. doi: 10.1016/j.jhep.2021.05.025</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pokorska-Śpiewak M., Kowalik-Mikołajewska B., Aniszewska M. et al. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest — comparison with histopathological assessment. Clin. Exp. Hepatol. 2017; 3 (4): 187-193. doi: 10.5114/ceh.2017.7107919</mixed-citation><mixed-citation xml:lang="en">Pokorska-Śpiewak M., Kowalik-Mikołajewska B., Aniszewska M. et al. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest — comparison with histopathological assessment. Clin. Exp. Hepatol. 2017; 3 (4): 187-193. doi: 10.5114/ceh.2017.7107919</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bril F., McPhaul M.J., Caulfield M.P. et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 dibetes mellitus. J. Investig. Med. 2019; 67: 303-311. doi: 10.1136/jim-2018-000864</mixed-citation><mixed-citation xml:lang="en">Bril F., McPhaul M.J., Caulfield M.P. et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 dibetes mellitus. J. Investig. Med. 2019; 67: 303-311. doi: 10.1136/jim-2018-000864</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Geervliet E., Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells. 2020; 9: 1212. doi: 10.3390/cells9051212</mixed-citation><mixed-citation xml:lang="en">Geervliet E., Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells. 2020; 9: 1212. doi: 10.3390/cells9051212</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J., Xu W., Chen Y. et al. Matrix metalloproteinase 9 facilitates hepatitis B virus replication through binding with type I interferon (IFN) receptor 1 to repress IFN/JAK/STAT signaling. J. Virol. 2017; 91 (8): e01824-16. doi: 10.1128/JVI.01824-16</mixed-citation><mixed-citation xml:lang="en">Chen J., Xu W., Chen Y. et al. Matrix metalloproteinase 9 facilitates hepatitis B virus replication through binding with type I interferon (IFN) receptor 1 to repress IFN/JAK/STAT signaling. J. Virol. 2017; 91 (8): e01824-16. doi: 10.1128/JVI.01824-16</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X., Maretti-Mira A.C., Wang L. et al. Liver-selective MMP- 9 inhibition in the rat eliminates ischemia-reperfusion injury and accelerates liver regeneration. Hepatology. 2019; 69: 314-328. doi: 10.1002/hep.30169</mixed-citation><mixed-citation xml:lang="en">Wang X., Maretti-Mira A.C., Wang L. et al. Liver-selective MMP- 9 inhibition in the rat eliminates ischemia-reperfusion injury and accelerates liver regeneration. Hepatology. 2019; 69: 314-328. doi: 10.1002/hep.30169</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ягода А.В., Корой П.В., Дудов Т.Р. Матриксные металлопротеиназы и морфологическая картина при хронических заболеваниях печени. Экспериментальная и клиническая гастроэнтерология. 2023; 218 (10): 153-159. doi: 10.31146/1682-8658-ecg-218-10-153-159</mixed-citation><mixed-citation xml:lang="en">Yagoda A.V., Koroy P.V., Dudov T.R. Matrix metalloproteinases and morphological features in chronic liver diseases. Experimental and Clinical Gastroenterology. 2023; 218 (10): 153-159. doi: 10.31146/1682-8658-ecg-218-10-153-159 [In Russian]</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Behairy O.G., El-Bakry M.M., Mansour A.I. et al. Matrix metalloproteinase-1 as a non-invasive biomarker to assess liver fibrosis in children with chronic liver disease. Egypt. Liver J. 2021; 11: 80. doi: 10.1186/s43066-021-00148-x</mixed-citation><mixed-citation xml:lang="en">Behairy O.G., El-Bakry M.M., Mansour A.I. et al. Matrix metalloproteinase-1 as a non-invasive biomarker to assess liver fibrosis in children with chronic liver disease. Egypt. Liver J. 2021; 11: 80. doi: 10.1186/s43066-021-00148-x</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lam S., Singh R., Dillman J.R. et al. Serum matrix metalloproteinase 7 is a diagnostic biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease. Hepatology Communications. 2020; 4 (11): 1680-1693. doi: 10.1002/hep4.1589</mixed-citation><mixed-citation xml:lang="en">Lam S., Singh R., Dillman J.R. et al. Serum matrix metalloproteinase 7 is a diagnostic biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease. Hepatology Communications. 2020; 4 (11): 1680-1693. doi: 10.1002/hep4.1589</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhan J., Wang J., Zhang Z. et al. Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase. Virulence. 2023; 14 (1). 2268497. doi: 10.1080/21505594.2023.2268497</mixed-citation><mixed-citation xml:lang="en">Zhan J., Wang J., Zhang Z. et al. Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase. Virulence. 2023; 14 (1). 2268497. doi: 10.1080/21505594.2023.2268497</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chen S., Huang H. Clinical non-invasive model to predict liver inflammation in chronic hepatitis B with alanine aminotransferase ≤ 2 upper limit of normal. Front. Med. 2021; 8: 661725. doi: 10.3389/fmed.2021.66172529</mixed-citation><mixed-citation xml:lang="en">Chen S., Huang H. Clinical non-invasive model to predict liver inflammation in chronic hepatitis B with alanine aminotransferase ≤ 2 upper limit of normal. Front. Med. 2021; 8: 661725. doi: 10.3389/fmed.2021.66172529</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang S., Wang J., Zhang Z. et al. Development and validation of a nomogram to predict significant liver inflammation in patients with chronic hepatitis B. Infect. Drug Resist. 2023; 16: 5065-5075. doi: 10.2147/IDR.S417007</mixed-citation><mixed-citation xml:lang="en">Jiang S., Wang J., Zhang Z. et al. Development and validation of a nomogram to predict significant liver inflammation in patients with chronic hepatitis B. Infect. Drug Resist. 2023; 16: 5065-5075. doi: 10.2147/IDR.S417007</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Li X., Xing Y., Zhou D. et al. A non-invasive model for predicting liver inflammation in chronic hepatitis B patients with normal serum alanine aminotransferase levels. Front. Med. 2021; 8: 688091. doi: 10.3389/fmed.2021.688091</mixed-citation><mixed-citation xml:lang="en">Li X., Xing Y., Zhou D. et al. A non-invasive model for predicting liver inflammation in chronic hepatitis B patients with normal serum alanine aminotransferase levels. Front. Med. 2021; 8: 688091. doi: 10.3389/fmed.2021.688091</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Xu W.S., Qiu X.M., Ou Q.S. et al. Red blood cell distribution width levels correlate with liver fibrosis and inflammation: a noninvasive serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis B. Medicine. 2015; 94 (10): e612. doi: 10.1097/MD.0000000000000612</mixed-citation><mixed-citation xml:lang="en">Xu W.S., Qiu X.M., Ou Q.S. et al. Red blood cell distribution width levels correlate with liver fibrosis and inflammation: a noninvasive serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis B. Medicine. 2015; 94 (10): e612. doi: 10.1097/MD.0000000000000612</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H., Xu H., Qu L. et al. Red blood cell distribution width and globulin, noninvasive indicators of fibrosis and inflammation in chronic hepatitis patients. Eur. J. Gastroenterol. Hepatol. 2016; 28: 997-1002. doi: 10.1097/MEG.0000000000000662</mixed-citation><mixed-citation xml:lang="en">Wang H., Xu H., Qu L. et al. Red blood cell distribution width and globulin, noninvasive indicators of fibrosis and inflammation in chronic hepatitis patients. Eur. J. Gastroenterol. Hepatol. 2016; 28: 997-1002. doi: 10.1097/MEG.0000000000000662</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yao M., Wang L., Wang J. et al. Diagnostic value of serum Golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis. Dis. Markers. 2022; 2022: 4253566. doi: 10.1155/2022/4253566</mixed-citation><mixed-citation xml:lang="en">Yao M., Wang L., Wang J. et al. Diagnostic value of serum Golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis. Dis. Markers. 2022; 2022: 4253566. doi: 10.1155/2022/4253566</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yao K., Wang J., Wang L. et al. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J. Med. Virol. 2022; 94 (2): 659-666. doi: 10.1002/jmv.27327</mixed-citation><mixed-citation xml:lang="en">Yao K., Wang J., Wang L. et al. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J. Med. Virol. 2022; 94 (2): 659-666. doi: 10.1002/jmv.27327</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J., Wang J., Yan X. et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol. Commun. 2022; 6 (4): 855- 866. doi: 10.1002/hep4.1859</mixed-citation><mixed-citation xml:lang="en">Liu J., Wang J., Yan X. et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol. Commun. 2022; 6 (4): 855- 866. doi: 10.1002/hep4.1859</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mussbacher M., Brunnthaler L., Panhuber A. et al. Till death do us part — the multifaceted role of platelets in liver diseases. Int. J. Mol. Sci. 2021; 22: 3113. doi: 10.3390/ijms22063113</mixed-citation><mixed-citation xml:lang="en">Mussbacher M., Brunnthaler L., Panhuber A. et al. Till death do us part — the multifaceted role of platelets in liver diseases. Int. J. Mol. Sci. 2021; 22: 3113. doi: 10.3390/ijms22063113</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Negrin L.L., Carlin G.L., Ristl R. et al. Serum levels of matrix metalloproteinases 1, 2, and 7, and their tissue inhibitors 1, 2, 3, and 4 in polytraumatized patients: time trajectories, correlations, and their ability to predict mortality. PLoS One. 2024; 19 (3): e0300258. doi: 10.1371/journal.pone.0300258</mixed-citation><mixed-citation xml:lang="en">Negrin L.L., Carlin G.L., Ristl R. et al. Serum levels of matrix metalloproteinases 1, 2, and 7, and their tissue inhibitors 1, 2, 3, and 4 in polytraumatized patients: time trajectories, correlations, and their ability to predict mortality. PLoS One. 2024; 19 (3): e0300258. doi: 10.1371/journal.pone.0300258</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Shan L., Wang F., Zhai D J. et al. Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis. Biomed. Pharmacother. 2023; 161: 114472. doi: 10.1016/j.biopha.2023.114472</mixed-citation><mixed-citation xml:lang="en">Shan L., Wang F., Zhai D J. et al. Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis. Biomed. Pharmacother. 2023; 161: 114472. doi: 10.1016/j.biopha.2023.114472</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Latronico T., Mascia C., Pati I. et al. Liver fibrosis in HCV monoinfected and HIV/HCV coinfected patients: dysregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) and effect of HCV protease inhibitors. Int. J. Mol. Sci. 2016; 17: 455. doi: 10.3390/ijms17040455</mixed-citation><mixed-citation xml:lang="en">Latronico T., Mascia C., Pati I. et al. Liver fibrosis in HCV monoinfected and HIV/HCV coinfected patients: dysregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) and effect of HCV protease inhibitors. Int. J. Mol. Sci. 2016; 17: 455. doi: 10.3390/ijms17040455</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Tsomidis I., Notas G., Xidakis C. et al. Enzymes of fibrosis in chronic liver disease. Biomedicines. 2022; 10 (12): 3179. doi: 10.3390/biomedicines10123179</mixed-citation><mixed-citation xml:lang="en">Tsomidis I., Notas G., Xidakis C. et al. Enzymes of fibrosis in chronic liver disease. Biomedicines. 2022; 10 (12): 3179. doi: 10.3390/biomedicines10123179</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ando W., Yokomori H., Tsutsui N. et al. Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin. Mol. Hepatol. 2018; 24 (1): 61-76. doi: 10.3350/cmh.2017.0030</mixed-citation><mixed-citation xml:lang="en">Ando W., Yokomori H., Tsutsui N. et al. Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin. Mol. Hepatol. 2018; 24 (1): 61-76. doi: 10.3350/cmh.2017.0030</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Castillo M., Hernandez-Barragan A., Flores-Vasconcelos I. et al. Production and activity of matrix metalloproteinases during liver fibrosis progression of chronic hepatitis C patients. World J. Hepatol. 2021; 13 (2): 218-232. doi: 10.4254/wjh.v13.i2.218</mixed-citation><mixed-citation xml:lang="en">Martinez-Castillo M., Hernandez-Barragan A., Flores-Vasconcelos I. et al. Production and activity of matrix metalloproteinases during liver fibrosis progression of chronic hepatitis C patients. World J. Hepatol. 2021; 13 (2): 218-232. doi: 10.4254/wjh.v13.i2.218</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Zdanowicz K., Kowalczuk-Kryston M., Olanski W. et al. Increase in serum MMP-9 and TIMP-1 concentrations during alcohol intoxication in adolescents — a preliminary study. Biomolecules. 2022; 12: 710. doi: 10.3390/biom12050710</mixed-citation><mixed-citation xml:lang="en">Zdanowicz K., Kowalczuk-Kryston M., Olanski W. et al. Increase in serum MMP-9 and TIMP-1 concentrations during alcohol intoxication in adolescents — a preliminary study. Biomolecules. 2022; 12: 710. doi: 10.3390/biom12050710</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Liu H., Xu L. Expression of MMP-9 in different degrees of chronic hepatitis B and its correlation with inflammation. Exp. Ther. Med. 2018; 16: 4136-4140. doi: 10.3892/etm.2018.6673</mixed-citation><mixed-citation xml:lang="en">Li Y., Liu H., Xu L. Expression of MMP-9 in different degrees of chronic hepatitis B and its correlation with inflammation. Exp. Ther. Med. 2018; 16: 4136-4140. doi: 10.3892/etm.2018.6673</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Yu D., Li Y., Xu Y. et al. Dysregulated matrix metalloproteinases and tissue inhibitors of metalloproteinase in residual splenic tissue after subtotal splenectomy due to portal hypertension. Int. J. Clin. Exp. Pathol. 2017; 10 (2): 1273-1282.</mixed-citation><mixed-citation xml:lang="en">Yu D., Li Y., Xu Y. et al. Dysregulated matrix metalloproteinases and tissue inhibitors of metalloproteinase in residual splenic tissue after subtotal splenectomy due to portal hypertension. Int. J. Clin. Exp. Pathol. 2017; 10 (2): 1273-1282.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Sufleţel R.T., Melincovici C.S., Gheban B.A. et al. Hepatic stellate cells — from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology. Rom. J. Morphol. Embryol. 2020; 61 (3): 615-642. doi: 10.47162/RJME.61.3.01</mixed-citation><mixed-citation xml:lang="en">Sufleţel R.T., Melincovici C.S., Gheban B.A. et al. Hepatic stellate cells — from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology. Rom. J. Morphol. Embryol. 2020; 61 (3): 615-642. doi: 10.47162/RJME.61.3.01</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Andrade T.G., Xavier L.C. D., Souza F.F. et al. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease — a survey in a university hospital in Brazil. Arch. Endocrinol. Metab. 2022; 66 (6): 823-830. doi: 10.20945/2359-3997000000514</mixed-citation><mixed-citation xml:lang="en">Andrade T.G., Xavier L.C. D., Souza F.F. et al. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease — a survey in a university hospital in Brazil. Arch. Endocrinol. Metab. 2022; 66 (6): 823-830. doi: 10.20945/2359-3997000000514</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Кравченко Ю.А., Корой П.В. «Воспалительный индекс» и гистологическая картина при неалкогольной жировой болезни печени. Медицинский вестник Северного Кавказа. 2023; 18 (4): 409-411. doi: 10.14300/mnnc.2023.18097</mixed-citation><mixed-citation xml:lang="en">Kravchenko Yu.A., Koroy P.V. «Inflammatory index» and histological features in nonalcoholic fatty liver disease. Medical News of North Caucasus. 2023; 18 (4): 409-411. doi: 10.14300/mnnc.2023.18097 [In Russian]</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ягода А.В., Корой П.В., Сляднев С.А. Положительная корреляция уровня молекул суперсемейства иммуноглобулинов ICAM-1, VCAM-1, PECAM-1 с показателями индекса фиброза при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2017; 138 (2): 45-51.</mixed-citation><mixed-citation xml:lang="en">Yagoda A.V., Koroy P.V., Slyadnev S.A. Positive correlation of the level of molecules of superfamily immunoglobulins ICAM-1, VCAM-1 and PECAM-1 with the index of fibrosis in nonalcoholic fatty liver disease. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2017; 138 (2): 45-51. [In Russian]</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
